LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-44.5% YoY

Gross Profit

$29M89.4% margin

Operating Income

$3M9.4% margin

Net Income

-$10M-31.3% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+24.7%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$769M

Total Liabilities

$101M

Stockholders' Equity

$668M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$59M	-44.5%
Gross Profit	$29M	$45M	-34.8%
Operating Income	$3M	$12M	-75.1%
Net Income	-$10M	$404,000	-2642.8%

Revenue Segments

Royalty

$24M36%

Kyprolis

$11M16%

Material Sales, Captisol

$9M13%

Material Sales, Captisol, Core

$9M13%

Royalty, Other

$4M7%

Rylaze

$4M6%

Teriparatide Injection

$3M4%

Evomela

$2M4%

Contract Revenue

$397,0001%

Service

$263,0000%

License Fees, Milestones, and Product, Other, Product, Other

$134,0000%

LGND Q3 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena